NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
07/30/2019
Back to search
Official data from USPTO
CHARIOTEER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
07/30/2019
Trademark type
Combined
Nice classes
5
Filing date
12/12/2008
Registration date
12/08/2009
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/30/2019
Last transaction
07/30/2019
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
Taizhou, CN
Examiner
LEE, DEBRA
Law office
M70
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of a stylized wheel and axle with two Chinese characters and the wording "CHARIOTEER" appearing beneath the design.
Holders and representatives
Holders
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Representatives
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antipyretycanalgesic and anti-inflammatory active pharmaceutical ingredientnaproxennaproxen sodiumnaproxen celecoxibnimesulideaceclofenacsulindacibuprofenfenoprofenketoprofencelecoxibnimesulideaceclofenac; anti-inflammatory active pharmaceutical ingredientnaproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredientaspirinacetaminophenpropyphenazone; antipyretic and analgesicantithrombotic active pharmaceutical ingredientindomethacin; analgesic active pharmaceutical ingredienteptazocineketorolac tromethamine; antipyreticanalgesic active pharmaceutical ingredientpropyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredientamantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredientflurbiprofenmeloxicamphenylbutazone; anti-platelet aggregation active pharmaceutical ingredientclopidogrel hydrogen sulfate; anti-platelet drugs active pharmaceutical ingredientprasugrel; anti-cancer active pharmaceutical ingredienttopotecan hydrochlorideifosfamidemesnairinotecancamptothecin7-ethyl-10-hydrol-camptothecindocetaxel; treating iodine deficiency active pharmaceutical ingredientiodine; anti-goitre expectoration and active pharmaceutical ingredientpotassium iodide; treating supraventricular arrhythmiatypical angina and variant angina active pharmaceutical ingredientdiltiazem; anti-hepatitis B virus active pharmaceutical ingredientadefovir dipivoxillamivudinetelbivudineclevudine; anti-urogenital system disease active pharmaceutical ingredientphenazopyridine hydrochloride; anti-virus active pharmaceutical ingredientacycloviracyclovir sodiumpenciclovirzidovudineganciclovirganciclovir sodiumfamciclovirvalaciclovir hydrochloridevalganciclovir hydrochlorideribavirin6-deoxyacyclovirpolyinosinic polycytidylic acidinterferonsadeninefarmivisendocosanolzanamviroseltamivirindinavirritonavirnelfinavirdelavirdineefavirenzainprenavirlopinavircidofovirimiquimoddidanosinefoscarnet sodiumpenciclovir sodiumstavudineabacavirtenofovir disoproxilemdtricitabinebrivudineamprenavirrimantadine; expectorant active pharmaceutical ingredientfudosteinecarbocisteine; anti-hypertension active pharmaceutical ingredientvalsartanlosartanirbesartantasosartancandesartantelmisartaneprosartanolmesartan; anxiolytic active pharmaceutical ingredientbrofoxine; treating coronary heart disease active pharmaceutical ingredientdipyridamole; immunosuppressive active pharmaceutical ingredienttacrolimus; immunosuppressive agents active pharmaceutical ingredientsirolimus; treating cardiac and cerebrovascular disease active pharmaceutical ingredientnicergoline; treating coronary heart disease active pharmaceutical ingredientisosorbide mononitrate; anti-obesity active pharmaceutical ingredientorlistat; antipsychotic active pharmaceutical ingredientperazine maleatecarisoprodol; anti-leprosy disease active pharmaceutical ingredientthalidomide; anti-vitamin deficiency active pharmaceutical ingredientfolic aciddexpanthenol; anti-megaloblastic anemia active pharmaceutical ingredientcalcium levofolinate; antithrombotic active pharmaceutical ingredientticlopidine hydrochloride; anti-rejection active pharmaceutical ingredientrapamycinmizoribinemycophenolic acidmycophenolate mofetilmycophenolate sodiumclarithromycindaptomycinmupirocinertapenemdoripenembiapenemmeropenemimipenemfaropenemaztreonambenflumetolmupirocincaspofungin; treating diabetes mellitus active pharmaceutical ingredientmetforminvoglibose; antioxidanttreatment heart disease and anti-hypertension active pharmaceutical ingredientcoenzyme Q10; treating brain edema and glaucoma active pharmaceutical ingredientisosorbide; anti-aids active pharmaceutical ingredientnevirapine
Publications
History of USPTO decisions and trademark events.
33 publications found
71AG
REGISTERED-SEC.71 ACCEPTED
07/30/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/26/2019
ES71
TEAS SECTION 71 RECEIVED
07/26/2019
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/28/2018
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
12/08/2018
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
01/15/2015
71AG
REGISTERED-SEC.71 ACCEPTED
01/15/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/15/2015
ES71
TEAS SECTION 71 RECEIVED
12/11/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/11/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/30/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/01/2010
FIMP
FINAL DISPOSITION PROCESSED
04/01/2010
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/09/2010
R.PR
REGISTERED-PRINCIPAL REGISTER
12/08/2009
PUBO
PUBLISHED FOR OPPOSITION
09/22/2009
NPUB
NOTICE OF PUBLICATION
09/02/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/18/2009
ALIE
ASSIGNED TO LIE
08/18/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/11/2009
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/20/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/15/2009
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/15/2009
RFNT
REFUSAL PROCESSED BY IB
05/22/2009
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/27/2009
RFRR
REFUSAL PROCESSED BY MPU
04/27/2009
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/26/2009
CNRT
NON-FINAL ACTION WRITTEN
04/25/2009
MAFR
APPLICATION FILING RECEIPT MAILED
04/21/2009
DOCK
ASSIGNED TO EXAMINER
04/17/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/17/2009
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/16/2009
Continuous trademark protection
Get notified about every new filing that threatens CHARIOTEER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.